Modulating nitric oxide signaling in the CNS for Alzheimer's disease therapy

Future Medicinal Chemistry

Volumn 5, Issue 12, 2013, Pages 1451-1468

  Zhihui, Qin ^a  

^a UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 [1 (2 FLUOROBENZYL) 1H PYRAZOLO[3,4 B]PYRIDIN 3 YL] 5 MORPHOLINO 4,6 PYRIMIDINEDIAMINE; 3 [2 (4 CHLOROPHENYLTHIO)PHENYL] N (4 DIMETHYLAMINOBUTYL)ACRYLAMIDE; 3' 5' CYCLIC GMP PHOSPHODIESTERASE 9A; 4 AMINO 5 CYCLOPROPYL 2 [1 (2 FLUOROBENZYL) 1H PYRAZOLO[3,4 B]PYRIDIN 3 YL]PYRIMIDINE; AMYLOID BETA PROTEIN; CELECOXIB; CFM 1571; CHOLINESTERASE INHIBITOR; CLOMETHIAZOLE; ENZYME INHIBITOR; FLURBIPROFEN; FLURBIPROFEN 4 NITROXYBUTYL ESTER; GT 1061; GUANYLATE CYCLASE ACTIVATOR; INDOMETACIN; LIFICIGUAT; NCX 2216; NEUROPROTECTIVE AGENT; NITRIC OXIDE; NONSTEROID ANTIINFLAMMATORY AGENT; PF 04447943; PHOSPHODIESTERASE; REACTIVE NITROGEN SPECIES; REACTIVE OXYGEN METABOLITE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE; SULINDAC; TACRINE; TAU PROTEIN; THIAZOLE DERIVATIVE; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ALZHEIMER DISEASE; AMNESIA; ANTIINFLAMMATORY ACTIVITY; BRAIN CORTEX; CEREBROVASCULAR ACCIDENT; COGNITION; DRUG BIOAVAILABILITY; EXCITOTOXICITY; HIPPOCAMPUS; HUMAN; IMMUNE RESPONSE; LEARNING; LONG TERM MEMORY; LONG TERM POTENTIATION; NERVE CELL PLASTICITY; NERVOUS SYSTEM INFLAMMATION; NEUROFIBRILLARY TANGLE; NEUROPATHOLOGY; NEUROPROTECTION; NEUROTRANSMISSION; NONHUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; REVIEW; SENILE PLAQUE; SIGNAL TRANSDUCTION; STRUCTURE ACTIVITY RELATION; SYNAPTIC TRANSMISSION;

EID: 84881529802     PISSN: 17568919     EISSN: 17568927     Source Type: Journal    
DOI: 10.4155/fmc.13.111     Document Type: Review

References (193)

1. Thies W, Bleiler L. 2011 Alzheimer's disease facts and figures. Alzheimers Dement. 7(2), 208-244 (2011).
2. Citron M. Alzheimer's disease: strategies for disease modification. Nat. Rev. Drug Discov. 9(5), 387-398 (2010).
3. Lleo A, Greenberg SM, Growdon JH. Current pharmacotherapy for Alzheimer's disease. Annu. Rev. Med. 57, 513-533 (2006).
4. Hardy J, Selkoe DJ. The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science 297(5580), 353-356 (2002).
5. Selkoe DJ. Resolving controversies on the path to Alzheimer's therapeutics. Nat. Med. 17(9), 1060-1065 (2011).
6. Brody DL, Holtzman DM. Active and passive immunotherapy for neurodegenerative disorders. Annu. Rev. Neurosci. 31, 175-193 (2008).
7. Jacobsen JS, Comery TA, Martone RL et al. Enhanced clearance of Ab in brain by sustaining the plasmin proteolysis cascade. Proc. Natl. Acad. Sci. USA 105(25), 8754-8759 (2008).
8. Imbimbo BP, Peretto I. Semagacestat, a g-secretase inhibitor for the potential treatment of Alzheimer's disease. Curr. Opin. Investig. Drugs 10(7), 721-730 (2009).
9. Martone RL, Zhou H, Atchison K et al. Begacestat (GSI-953): a novel, selective thiophene sulfonamide inhibitor of amyloid precursor protein g-secretase for the treatment of Alzheimer's disease. J. Pharmacol. Exp. Ther. 331(2), 598-608 (2009).
10. McLaurin J, Kierstead ME, Brown ME et al. Cyclohexanehexol inhibitors of Ab aggregation prevent and reverse Alzheimer phenotype in a mouse model. Nat. Med. 12(7), 801-808 (2006).
11. Gervais F, Paquette J, Morissette C et al. Targeting soluble Ab peptide with tramiprosate for the treatment of brain amyloidosis. Neurobiol. Aging 28(4), 537-547 (2007).
12. Imbimbo BP. Why Did tarenflurbil fail in Alzheimer's disease? J. Alzheimers Dis. 17(4), 757-760 (2009).
13. Sabbagh MN. Drug development for Alzheimer's disease: where are we now and where are we headed? Am. J. Geriatr. Pharmacother. 7(3), 167-185 (2009).
14. Extance A. Alzheimer's failure raises questions about disease-modifying strategies. Nat. Rev. Drug Discov. 9(10), 749-751 (2010).
15. Cummings J. What can be inferred from the interruption of the semagacestat trial for treatment of Alzheimer's disease? Biol. Psychiatry 68(10), 876-878 (2010).
16. Mangialasche F, Solomon A, Winblad B, Mecocci P, Kivipelto M. Alzheimer's disease: clinical trials and drug development. Lancet Neurol. 9(7), 702-716 (2010).
17. Puzzo D, Vitolo O, Trinchese F, Jacob JP, Palmeri A, Arancio O. Amyloid-b peptide inhibits activation of the nitric oxide/cGMP/cAMP-responsive element-binding protein pathway during hippocampal synaptic plasticity. J. Neurosci. 25(29), 6887-6897 (2005).
18. Thatcher GR, Bennett BM, Reynolds JN. Nitric oxide mimetic molecules as therapeutic agents in Alzheimer's disease. Curr. Alzheimer Res. 2(2), 171-182 (2005).
19. Puzzo D, Staniszewski A, Deng SX et al. Phosphodiesterase 5 inhibition improves synaptic function, memory, and amyloid-b load in an Alzheimer's disease mouse model. J. Neurosci. 29(25), 8075-8086 (2009).
20. Guix FX, Uribesalgo I, Coma M, Munoz FJ. The physiology and pathophysiology of nitric oxide in the brain. Prog. Neurobiol. 76(2), 126-152 (2005).
21. Calabrese V, Mancuso C, Calvani M, Rizzarelli E, Butterfield DA, Stella AM. Nitric oxide in the central nervous system: neuroprotection versus neurotoxicity. Nat. Rev. Neurosci. 8(10), 766-775 (2007).
22. Prast H, Philippu A. Nitric oxide as modulator of neuronal function. Prog. Neurobiol. 64(1), 51-68 (2001).
23. Hawkins RD. NO honey, I don't remember. Neuron 16(3), 465-467 (1996).
24. Garthwaite J. Glutamate, nitric oxide and cell-cell signalling in the nervous system. Trends Neurosci. 14(2), 60-67 (1991).
25. Lu YF, Kandel ER, Hawkins RD. Nitric oxide signaling contributes to late-phase LTP and CREB phosphorylation in the hippocampus. J. Neurosci. 19(23), 10250-10261 (1999).
26. Josselyn SA, Nguyen PV. CREB, synapses and memory disorders: past progress and future challenges. Curr. Drug Targets CNS Neurol. Disord. 4(5), 481-497 (2005).
27. Silva AJ, Kogan JH, Frankland PW, Kida S. CREB and memory. Annu. Rev. Neurosci. 21, 127-148 (1998).
28. Bliss TV, Collingridge GL. A synaptic model of memory: long-term potentiation in the hippocampus. Nature 361(6407), 31-39 (1993).
29. Arancio O, Kandel ER, Hawkins RD. Activity-dependent long-term enhancement of transmitter release by presynaptic 3',5'-cyclic GMP in cultured hippocampal neurons. Nature 376(6535), 74-80 (1995).
30. Arancio O, Kiebler M, Lee CJ et al. Nitric oxide acts directly in the presynaptic neuron to produce long-term potentiation in cultured hippocampal neurons. Cell 87(6), 1025-1035 (1996).
31. Arancio O, Antonova I, Gambaryan S et al. Presynaptic role of cGMP-dependent protein kinase during long-lasting potentiation. J. Neurosci. 21(1), 143-149 (2001).
32. Venturini G, Colasanti M, Persichini T et al. b-amyloid inhibits NOS activity by subtracting NADPH availability. FASEB J. 16(14), 1970-1972 (2002).
33. Baltrons MA, Pedraza CE, Heneka MT, Garcia A. b-amyloid peptides decrease soluble guanylyl cyclase expression in astroglial cells. Neurobiol. Dis. 10(2), 139-149 (2002).
34. Bonkale WL, Winblad B, Ravid R, Cowburn RF. Reduced nitric oxide responsive soluble guanylyl cyclase activity in the superior temporal cortex of patients with Alzheimer's disease. Neurosci. Lett. 187(1), 5-8 (1995).
35. Suhara T, Magrane J, Rosen K et al. Ab42 generation is toxic to endothelial cells and inhibits eNOS function through an Akt/GSK-3beta signaling-dependent mechanism. Neurobiol. Aging 24(3), 437-451 (2003).
36. Miller TW, Isenberg JS, Shih HB, Wang Y, Roberts DD. Amyloid-b inhibits NO-cGMP signaling in a CD36- and CD47-dependent manner. PLoS ONE 5(12), e15686 (2011).
37. Greenberg ME, Ziff EB, Greene LA. Stimulation of neuronal acetylcholine receptors induces rapid gene transcription. Science 234(4772), 80-83 (1986).
38. Montminy MR, Bilezikjian LM. Binding of a nuclear protein to the cyclic-AMP response element of the somatostatin gene. Nature 328(6126), 175-178 (1987).
39. Bito H, Deisseroth K, Tsien RW. CREB phosphorylation and dephosphorylation: a Ca2+- and stimulus duration-dependent switch for hippocampal gene expression. Cell 87(7), 1203-1214 (1996).
40. Alberini CM. Transcription factors in long-term memory and synaptic plasticity. Physiol. Rev. 89(1), 121-145 (2009).
41. Zheng Z, Sabirzhanov B, Keifer J. Oligomeric amyloid-b inhibits the proteolytic conversion of brain-derived neurotrophic factor (BDNF), AMPA receptor trafficking, and classical conditioning. J. Biol. Chem. 285(45), 34708-34717 (2010).
42. Ma QL, Harris-White ME, Ubeda OJ et al. Evidence of Ab-and transgene-dependent defects in ERK-CREB signaling in Alzheimer's models. J. Neurochem. 103(4), 1594-1607 (2007).
43. Espana J, Valero J, Minano-Molina AJ et al. b-Amyloid disrupts activity-dependent gene transcription required for memory through the CREB coactivator CRTC1. J. Neurosci. 30(28), 9402-9410 (2010).
44. Saura CA, Valero J. The role of CREB signaling in Alzheimer's disease and other cognitive disorders. Rev. Neurosci. 22(2), 153-169 (2011).
45. Riccio A, Alvania RS, Lonze BE et al. A nitric oxide signaling pathway controls CREB-mediated gene expression in neurons. Mol. Cell 21(2), 283-294 (2006).
46. Puzzo D, Palmeri A, Arancio O. Involvement of the nitric oxide pathway in synaptic dysfunction following amyloid elevation in Alzheimer's disease. Rev. Neurosci. 17(5), 497-523 (2006).
47. Paul C, Stratil C, Hofmann F, Kleppisch T. cGMP-dependent protein kinase type I promotes CREB/CRE-mediated gene expression in neurons of the lateral amygdala. Neurosci. Lett. 473(2), 82-86 (2010).
48. Zhuo M, Hu Y, Schultz C, Kandel ER, Hawkins RD. Role of guanylyl cyclase and cGMP-dependent protein kinase in long-term potentiation. Nature 368(6472), 635-639 (1994).
49. Shahani N, Sawa A. Protein S-nitrosylation: role for nitric oxide signaling in neuronal death. Biochim. Biophys. Acta 1820(6), 736-742 (2012).
50. Pacher P, Beckman JS, Liaudet L. Nitric oxide and peroxynitrite in health and disease. Physiol. Rev. 87(1), 315-424 (2007).
51. Sultana R, Poon HF, Cai J et al. Identification of nitrated proteins in Alzheimer's disease brain using a redox proteomics approach. Neurobiol. Dis. 22(1), 76-87 (2006).
52. Castegna A, Thongboonkerd V, Klein JB, Lynn B, Markesbery WR, Butterfield DA. Proteomic identification of nitrated proteins in Alzheimer's disease brain. J. Neurochem. 85(6), 1394-1401 (2003).
53. Austin SA, Santhanam AV, Katusic ZS. Endothelial nitric oxide modulates expression and processing of amyloid precursor protein. Circ. Res. 107(12), 1498-1502 (2010).
54. Chu Y, Heistad DD. No answer to Alzheimer's disease? Circ. Res. 107(12), 1400-1402 (2010).
55. Ciani E, Guidi S, Bartesaghi R, Contestabile A. Nitric oxide regulates cGMP-dependent cAMP-responsive element binding protein phosphorylation and Bcl-2 expression in cerebellar neurons: implication for a survival role of nitric oxide. J. Neurochem. 82(5), 1282-1289 (2002).
56. Ha KS, Kim KM, Kwon YG et al. Nitric oxide prevents 6-hydroxydopamine- induced apoptosis in PC12 cells through cGMP-dependent PI3 kinase/Akt activation. FASEB J. 17(9), 1036-1047 (2003).
57. Lipton SA, Rosenberg PA. Excitatory amino acids as a final common pathway for neurologic disorders. N. Engl. J. Med. 330(9), 613-622 (1994).
58. Choi YB, Tenneti L, Le DA et al. Molecular basis of NMDA receptor-coupled ion channel modulation by S-nitrosylation. Nat. Neurosci. 3(1), 15-21 (2000).
59. Melino G, Bernassola F, Knight RA, Corasaniti MT, Nistico G, Finazzi-Agro A. S-nitrosylation regulates apoptosis. Nature 388(6641), 432-433 (1997).
60. Mannick JB, Schonhoff C, Papeta N et al. S-Nitrosylation of mitochondrial caspases. J. Cell. Biol. 154(6), 1111-1116 (2001).
61. Tenneti L, D'Emilia DM, Lipton SA. Suppression of neuronal apoptosis by S-nitrosylation of caspases. Neurosci. Lett. 236(3), 139-142 (1997).
62. Zhou P, Qian L, Iadecola C. Nitric oxide inhibits caspase activation and apoptotic morphology but does not rescue neuronal death. J. Cereb. Blood Flow Metab. 25(3), 348-357 (2005).
63. Fahnestock M, Marchese M, Head E et al. BDNF increases with behavioral enrichment and an antioxidant diet in the aged dog. Neurobiol. Aging 33(3), 546-554 (2010).
64. Lazarov O, Robinson J, Tang YP et al. Environmental enrichment reduces Ab levels and amyloid deposition in transgenic mice. Cell 120(5), 701-713 (2005).
65. Selkoe DJ. Alzheimer's disease is a synaptic failure. Science 298(5594), 789-791 (2002).
66. Domek-Lopacinska KU, Strosznajder JB. Cyclic GMP and nitric oxide synthase in aging and Alzheimer's disease. Mol. Neurobiol. 41(2-3), 129-137 (2010).
67. Thatcher GR, Bennett BM, Dringenberg HC, Reynolds JN. Novel nitrates as NO mimetics directed at Alzheimer's disease. J. Alzheimers Dis. 6(6 Suppl.), S75-84 (2004).
68. Bennett BM, Reynolds JN, Prusky GT, Douglas RM, Sutherland RJ, Thatcher GRJ. Cognitive deficits in rats after forebrain cholinergic depletion are reversed by a novel NO mimetic nitrate ester. Neuropsychopharmacology 32(3), 505-513 (2007).
69. Wirtz-Brugger F, Giovanni A. Guanosine 3',5'-cyclic monophosphate mediated inhibition of cell death induced by nerve growth factor withdrawal and b-amyloid: protective effects of propentofylline. Neuroscience 99(4), 737-750 (2000).
70. Paris D, Town T, Parker T, Humphrey J, Mullan M. b-amyloid vasoactivity and proinflammation in microglia can be blocked by cGMP-elevating agents. Ann. NY. Acad. Sci. 903, 446-450 (2000).
71. Reynolds JN, Bennett BM, Boegman RJ et al. Neuroprotection against ischemic brain injury conferred by a novel nitrate ester. Bioorg. Med. Chem. Lett. 12(20), 2863-2866 (2002).
72. Smith S, Dringenberg HC, Bennett BM, Thatcher GR, Reynolds JN. A novel nitrate ester reverses the cognitive impairment caused by scopolamine in the Morris water maze. Neuroreport 11(17), 3883-3886 (2000).
73. Cavalli A, Bolognesi ML, Minarini A et al. Multi-target-directed ligands to combat neurodegenerative diseases. J. Med. Chem. 51(3), 347-372 (2008).
74. DiFabio J, Ji Y, Vasiliou V, Thatcher GRJ, Bennett BM. Role of mitochondrial aldehyde dehydrogenase in nitrate tolerance. Mol. Pharmacol. 64(5), 1109-1116 (2003).
75. D'Souza Y, Ji Y, Bennett B. Effect of overexpression of human aldehyde dehydrogenase 2 in LLC-PK1 cells on glyceryl trinitrate biotransformation and cGMP accumulation. Br. J. Pharmacol. 168(4), 978-987 (2013).
76. Thatcher GRJ, Nicolescu AC, Bennett BM, Toader V. Nitrates and NO release: contemporary aspects in biological and medicinal chemistry. Free Radic. Biol. Med. 37(8), 1122-1143 (2004).
77. Lundberg JO, Gladwin MT, Ahluwalia A et al. Nitrate and nitrite in biology, nutrition and therapeutics. Nat. Chem. Biol. 5(12), 865-869 (2009).
78. Harkany T, Abraham I, Timmerman W et al. b-amyloid neurotoxicity is mediated by a glutamate-triggered excitotoxic cascade in rat nucleus basalis. Eur. J. Neurosci. 12(8), 2735-2745 (2000).
79. Louzada PR, Paula Lima AC, Mendonca-Silva DL, Noel F, De Mello FG, Ferreira ST. Taurine prevents the neurotoxicity of b-amyloid and glutamate receptor agonists: activation of GABA receptors and possible implications for Alzheimer's disease and other neurological disorders. FASEB J. 18(3), 511-518 (2004).
80. Lin X, Jun-Tian Z. Neuroprotection by d-securinine against neurotoxicity induced by b-amyloid (25-35). Neurol. Res. 26(7), 792-796 (2004).
81. Lee BY, Ban JY, Seong YH. Chronic stimulation of GABAA receptor with muscimol reduces amyloid beta protein (25-35)-induced neurotoxicity in cultured rat cortical cells. Neurosci. Res. 52(4), 347-356 (2005).
82. Marcade M, Bourdin J, Loiseau N et al. Etazolate, a neuroprotective drug linking GABAA receptor pharmacology to amyloid precursor protein processing. J. Neurochem. 106(1), 392-404 (2008).
83. Limon A, Reyes-Ruiz JM, Miledi R. Loss of functional GABAA receptors in the Alzheimer diseased brain. Proc. Natl. Acad. Sci. USA 109(25), 10071-10076 (2012).
84. Vellas B, Sol O, Snyder PJ et al. EHT0202 in Alzheimer's disease: a 3-month, randomized, placebo-controlled, double-blind study. Curr. Alzheimer Res. 8(2), 203-212 (2011).
85. Nelson RM, Hainsworth AH, Lambert DG et al. Neuroprotective efficacy of AR-A008055, a clomethiazole analogue, in a global model of acute ischaemic stroke and its effect on ischaemia-induced glutamate and GABA efflux in vitro. Neuropharmacology 41(2), 159-166 (2001).
86. Green AR, Hainsworth AH, Misra A et al. The interaction of AR-A008055 and its enantiomers with the GABAA receptor complex and their sedative, muscle relaxant and anticonvulsant activity. Neuropharmacology 41(2), 167-174 (2001).
87. Colado MI, O'Shea E, Esteban B, Green AR. Studies on the neuroprotective effect of the enantiomers of AR-A008055, a compound structurally related to clomethiazole, on MDMA ('ecstasy')-induced neurodegeneration in rat brain. Psychopharmacology (Berl.) 157(1), 82-88 (2001).
88. Harmon D, Coleman E, Marshall C, Lan W, Shorten G. The effect of clomethiazole on plasma concentrations of interleukin-6, -8, -1b, tumor necrosis factor-a, and neutrophil adhesion molecule expression during experimental extracorporeal circulation. Anesth. Analg. 97(1), 13-18 (2003).
89. Clarkson AN, Liu H, Rahman R, Jackson DM, Appleton I, Kerr DS. Clomethiazole: mechanisms underlying lasting neuroprotection following hypoxia-ischemia. FASEB J. 19(8), 1036-1038 (2005).
90. Wilby MJ, Hutchinson PJ. The pharmacology of chlormethiazole: a potential neuroprotective agent? CNS Drug Rev. 10(4), 281-294 (2004).
91. Clarkson AN, Clarkson J, Jackson DM, Sammut IA. Mitochondrial involvement in transhemispheric diaschisis following hypoxia-ischemia: clomethiazole- mediated amelioration. Neuroscience 144(2), 547-561 (2007).
92. Gilby KL, Sydserff SG, Robertson HA. Differential neuroprotective effects for three GABA-potentiating compounds in a model of hypoxia-ischemia. Brain Res. 1035(2), 196-205 (2005).
93. Green AR, Hainsworth AH, Jackson DM. GABA potentiation: a logical pharmacological approach for the treatment of acute ischaemic stroke. Neuropharmacology 39(9), 1483-1494 (2000).
94. Shi JQ, Shen W, Chen J et al. Anti-TNF-a reduces amyloid plaques and tau phosphorylation and induces CD11c-positive dendritic-like cell in the APP/PS1 transgenic mouse brains. Brain Res. 1368, 239-247 (2011).
95. Alvarez A, Cacabelos R, Sanpedro C, Garcia-Fantini M, Aleixandre M. Serum TNF-a levels are increased and correlate negatively with free IGF-I in Alzheimer disease. Neurobiol. Aging 28(4), 533-536 (2007).
96. McAlpine FE, Lee JK, Harms AS et al. Inhibition of soluble TNF signaling in a mouse model of Alzheimer's disease prevents pre-plaque amyloid-associated neuropathology. Neurobiol. Dis. 34(1), 163-177 (2009).
97. Abdul-Hay S, Schiefer IT, Chandrasena RE et al. NO-SSRIs: nitric oxide chimera drugs incorporating a selective serotonin reuptake inhibitor. ACS Med. Chem. Lett. 2(9), 656-661 (2011).
98. Caraci F, Copani A, Nicoletti F, Drago F. Depression and Alzheimer's disease: neurobiological links and common pharmacological targets. Eur. J. Pharmacol. 626(1), 64-71 (2010).
99. Sierksma AS, van den Hove DL, Steinbusch HW, Prickaerts J. Major depression, cognitive dysfunction and Alzheimer's disease: is there a link? Eur. J. Pharmacol. 626(1), 72-82 (2010).
100. Qin Z, Luo J, VandeVrede L et al. Design and synthesis of neuroprotective methylthiazoles and modification as NO-chimeras for neurodegenerative therapy. J. Med. Chem. 55(15), 6784-6801 (2012).
101. Eikelenboom P, Veerhuis R, Scheper W, Rozemuller AJ, van Gool WA, Hoozemans JJ. The significance of neuroinflammation in understanding Alzheimer's disease. J. Neural. Transm. 113(11), 1685-1695 (2006).
102. Arnaud L, Robakis NK, Figueiredo-Pereira ME. It may take inflammation, phosphorylation and ubiquitination to 'tangle' in Alzheimer's disease. Neurodegener. Dis. 3(6), 313-319 (2006).
103. Lleo A, Galea E, Sastre M. Molecular targets of non-steroidal anti-inflammatory drugs in neurodegenerative diseases. Cell. Mol. Life Sci. 64(11), 1403-1418 (2007).
104. Weggen S, Eriksen JL, Das P et al. A subset of NSAIDs lower amyloidogenic Ab42 independently of cyclooxygenase activity. Nature 414(6860), 212-216 (2001).
105. Lim GP, Yang F, Chu T et al. Ibuprofen suppresses plaque pathology and inflammation in a mouse model for Alzheimer's disease. J. Neurosci. 20(15), 5709-5714 (2000).
106. Jantzen PT, Connor KE, DiCarlo G et al. Microglial activation and b-amyloid deposit reduction caused by a nitric oxide-releasing nonsteroidal anti-inflammatory drug in amyloid precursor protein plus presenilin-1 transgenic mice. J. Neurosci. 22(6), 2246-2254 (2002).
107. Yan Q, Zhang J, Liu H et al. Anti-inflammatory drug therapy alters b-amyloid processing and deposition in an animal model of Alzheimer's disease. J. Neurosci. 23(20), 7504-7509 (2003).
108. Sastre M, Dewachter I, Rossner S et al. Nonsteroidal anti-inflammatory drugs repress b-secretase gene promoter activity by the activation of PPARg. Proc. Natl. Acad. Sci. USA 103(2), 443-448 (2006).
109. Zhou Y, Su Y, Li B et al. Nonsteroidal anti-inflammatory drugs can lower amyloidogenic Ab42 by inhibiting Rho. Science 302(5648), 1215-1217 (2003).
110. You X, Zhang YW, Chen Y et al. Retinoid X receptor-a mediates (R)-flurbiprofen's effect on the levels of Alzheimer's b-amyloid. J. Neurochem 111(1), 142-149 (2009).
111. Abdul-Hay SO, Edirisinghe P, Thatcher GR. Selective modulation of amyloid-beta peptide degradation by flurbiprofen, fenofibrate, and related compounds regulates Abeta levels. J. Neurochem. 111(3), 683-695 (2009).
112. Abdul-Hay SO, Luo J, Ashghodom RT, Thatcher GR. NO-flurbiprofen reduces amyloid-b, is neuroprotective in cell culture, and enhances cognition in response to cholinergic blockade. J. Neurochem. 111(3), 766-776 (2009).
113. Schiefer IT, Abdul-Hay S, Wang H, Vanni M, Qin Z, Thatcher GR. Inhibition of amyloidogenesis by nonsteroidal anti-inflammatory drugs and their hybrid nitrates. J. Med. Chem. 54(7), 2293-2306 (2011).
114. Kukar TL, Ladd TB, Bann MA et al. Substrate-targeting g-secretase modulators. Nature 453(7197), 925-929 (2008).
115. Beher D, Clarke EE, Wrigley JD et al. Selected non-steroidal anti-inflammatory drugs and their derivatives target g-secretase at a novel site. Evidence for an allosteric mechanism. J. Biol. Chem. 279(42), 43419-43426 (2004).
116. Lleo A, Berezovska O, Herl L et al. Nonsteroidal anti-inflammatory drugs lower Ab42 and change presenilin 1 conformation. Nat. Med. 10(10), 1065-1066 (2004).
117. Choi SH, Aid S, Caracciolo L et al. Cyclooxygenase-1 inhibition reduces amyloid pathology and improves memory deficits in a mouse model of Alzheimer's disease. J. Neurochem. 124(1), 59-68 (2013).
118. James DS. The multisystem adverse effects of NSAID therapy. J. Am. Osteopath. Assoc. 99(11 Suppl.), S1-S7 (1999).
119. Laine L. The gastrointestinal effects of nonselective NSAIDs and COX-2-selective inhibitors. Semin. Arthritis Rheum. 32(3 Suppl. 1), 25-32 (2002).
120. Aisen PS, Schafer KA, Grundman M et al. Effects of rofecoxib or naproxen vs placebo on Alzheimer disease progression: a randomized controlled trial. JAMA 289(21), 2819-2826 (2003).
121. Aisen PS, Thal LJ, Ferris SH et al. Rofecoxib in patients with mild cognitive impairment: further analyses of data from a randomized, double-blind, trial. Curr. Alzheimer Res. 5(1), 73-82 (2008).
122. Soininen H, West C, Robbins J, Niculescu L. Long-term efficacy and safety of celecoxib in Alzheimer's disease. Dement. Geriatr. Cogn. Disord. 23(1), 8-21 (2007).
123. Kukar T, Murphy MP, Eriksen JL et al. Diverse compounds mimic Alzheimer disease-causing mutations by augmenting Ab42 production. Nat. Med. 11(5), 545-550 (2005).
124. Green RC, Schneider LS, Amato DA et al. Effect of tarenflurbil on cognitive decline and activities of daily living in patients with mild Alzheimer disease: a randomized controlled trial. JAMA 302(23), 2557-2564 (2009).
125. Marder K. Tarenflurbil in patients with mild Alzheimer's disease. Curr. Neurol. Neurosci. Rep. 10(5), 336-337 (2010).
126. Lanas A. Role of nitric oxide in the gastrointestinal tract. Arthritis Res. Ther. 10 Suppl 2, S4 (2008).
127. Calatayud S, Barrachina D, Esplugues JV. Nitric oxide: relation to integrity, injury, and healing of the gastric mucosa. Microsc. Res. Tech. 53(5), 325-335 (2001).
128. Koc, Kucukguzel SG. Medicinal chemistry and anti-inflammatory activity of nitric oxide-releasing NSAI drugs. Mini-Rev. Med. Chem. 9(5), 611-619 (2009).
129. Velazquez CA, Chen QH, Citro ML, Keefer LK, Knaus EE. Second-generation aspirin and indomethacin prodrugs possessing an O2-(acetoxymethyl)-1-(2- carboxypyrrolidin- 1-yl)diazenium-1,2-diolate nitric oxide donor moiety: design, synthesis, biological evaluation, and nitric oxide release studies. J. Med. Chem. 51(6), 1954-1961 (2008).
130. de Carvalho PS, Marostica M, Gambero A, Pedrazzoli J Jr. Synthesis and pharmacological characterization of a novel nitric oxide-releasing diclofenac derivative containing a benzofuroxan moiety. Eur. J. Med. Chem. 45(6), 2489-2493 (2010).
131. Huang Z, Velazquez CA, Abdellatif KR et al. Ethanesulfohydroxamic acid ester prodrugs of nonsteroidal anti-inflammatory drugs (NSAIDs): synthesis, nitric oxide and nitroxyl release, cyclooxygenase inhibition, anti-inflammatory, and ulcerogenicity index studies. J. Med. Chem. 54(5), 1356-1364 (2011).
132. Bandarage UK, Chen L, Fang X et al. Nitrosothiol esters of diclofenac: synthesis and pharmacological characterization as gastrointestinal-sparing prodrugs. J. Med. Chem. 43(21), 4005-4016 (2000).
133. Bolla M, Almirante N, Benedini F. Therapeutic potential of nitrate esters of commonly used drugs. Curr. Top Med. Chem. 5(7), 707-720 (2005).
134. Ongini E, Bolla M. Nitric oxide based nonsteroidal anti-inflammatory agents. Drug Discov. Today 3, 395-400 (2006).
135. Eriksen JL, Sagi SA, Smith TE et al. NSAIDs and enantiomers of flurbiprofen target g-secretase and lower Ab 42 in vivo. J. Clin. Invest. 112(3), 440-449 (2003).
136. Wallace JL, Muscara MN, de Nucci G et al. Gastric tolerability and prolonged prostaglandin inhibition in the brain with a nitric oxide-releasing flurbiprofen derivative, NCX-2216 [3-[4-(2-fluoro-alpha-methyl- [1,1'-biphenyl]-4-acetyloxy)-3- methoxyphenyl]-2-prop enoic acid 4-nitrooxy butyl ester]. J. Pharmacol. Exp. Ther. 309(2), 626-633 (2004).
137. van Groen T, Kadish I. Transgenic AD model mice, effects of potential anti-AD treatments on inflammation and pathology. Brain Res. Brain Res. Rev. 48(2), 370-378 (2005).
138. Prosperi C, Scali C, Barba M et al. Comparison between flurbiprofen and its nitric oxide-releasing derivatives HCT-1026 and NCX-2216 on Ab1-42-induced brain inflammation and neuronal damage in the rat. Int. J. Immunopathol. Pharmacol. 17(3), 317-330 (2004).
139. Christensen DD. Changing the course of Alzheimer's disease: anti-amyloid disease-modifying treatments on the horizon. Prim. Care Companion J. Clin. Psychiatry 9(1), 32-41 (2007).
140. Peretto I, Radaelli S, Parini C et al. Synthesis and biological activity of flurbiprofen analogues as selective inhibitors of b-amyloid1-42 secretion. J. Med. Chem. 48(18), 5705-5720 (2005).
141. Imbimbo BP, Giardino L, Sivilia S et al. CHF5074, a novel g-secretase modulator, restores hippocampal neurogenesis potential and reverses contextual memory deficit in a transgenic mouse model of Alzheimer's disease. J. Alzheimers Dis. 20(1), 159-173 (2010).
142. Lee YJ, Han SB, Nam SY, Oh KW, Hong JT. Inflammation and Alzheimer's disease. Arch. Pharm. Res. 33(10), 1539-1556 (2010).
143. Ballard CG. Advances in the treatment of Alzheimer's disease: benefits of dual cholinesterase inhibition. Eur. Neurol. 47(1), 64-70 (2002).
144. Kopf SR, Benton RS, Kalfin R, Giovannini MG, Pepeu G. NO synthesis inhibition decreases cortical ACh release and impairs retention of a conditioned response. Brain Res. 894(1), 141-144 (2001).
145. Crismon ML. Tacrine: first drug approved for Alzheimer's disease. Ann. Pharmacother. 28(6), 744-751 (1994).
146. Fang L, Appenroth D, Decker M et al. Synthesis and biological evaluation of NO-donor-tacrine hybrids as hepatoprotective anti-Alzheimer drug candidates. J. Med. Chem. 51(4), 713-716 (2008).
147. Fang L, Appenroth D, Decker M et al. NO-donating tacrine hybrid compounds improve scopolamine-induced cognition impairment and show less hepatotoxicity. J. Med. Chem. 51(24), 7666-7669 (2008).
148. Gracon SI, Knapp MJ, Berghoff WG et al. Safety of tacrine: clinical trials, treatment IND, and postmarketing experience. Alzheimer Dis. Assoc. Disord. 12(2), 93-101 (1998).
149. Futter LE, al-Swayeh OA, Moore PK. A comparison of the effect of nitroparacetamol and paracetamol on liver injury. Br. J. Pharmacol. 132(1), 10-12 (2001).
150. Chen Y, Sun J, Fang L et al. Tacrine-ferulic acid-nitric oxide (NO) donor trihybrids as potent, multifunctional acetyl-and butyrylcholinesterase inhibitors. J. Med. Chem. 55(9), 4309-4321 (2012).
151. Evgenov OV, Pacher P, Schmidt PM, Hasko G, Schmidt HH, Stasch JP. NO-independent stimulators and activators of soluble guanylate cyclase: discovery and therapeutic potential. Nat. Rev. Drug Discov. 5(9), 755-768 (2006).
152. Munzel T, Daiber A, Mulsch A. Explaining the phenomenon of nitrate tolerance. Circ. Res. 97(7), 618-628 (2005).
153. Li Y, Zhang D, Jin W et al. Mitochondrial aldehyde dehydrogenase-2 (ALDH2) Glu504Lys polymorphism contributes to the variation in efficacy of sublingual nitroglycerin. J. Clin. Invest. 116(2), 506-511 (2006).
154. Dikalov S, Fink B, Skatchkov M, Stalleicken D, Bassenge E. Formation of reactive oxygen species by pentaerithrityltetranitrate and glyceryl trinitrate in vitro and development of nitrate tolerance. J. Pharmacol. Exp. Ther. 286(2), 938-944 (1998).
155. Hoenicka M, Becker EM, Apeler H et al. Purified soluble guanylyl cyclase expressed in a baculovirus/Sf9 system: stimulation by YC-1, nitric oxide, and carbon monoxide. J. Mol. Med. (Berl.) 77(1), 14-23 (1999).
156. Artz JD, Toader V, Zavorin SI, Bennett BM, Thatcher GR. In vitro activation of soluble guanylyl cyclase and nitric oxide release: a comparison of NO donors and NO mimetics. Biochemistry 40(31), 9256-9264 (2001).
157. Russwurm M, Mergia E, Mullershausen F, Koesling D. Inhibition of deactivation of NO-sensitive guanylyl cyclase accounts for the sensitizing effect of YC-1. J. Biol. Chem. 277(28), 24883-24888 (2002).
158. Friebe A, Mullershausen F, Smolenski A, Walter U, Schultz G, Koesling D. YC-1 potentiates nitric oxide-and carbon monoxide-induced cyclic GMP effects in human platelets. Mol. Pharmacol. 54(6), 962-967 (1998).
159. Chien WL, Liang KC, Teng CM, Kuo SC, Lee FY, Fu WM. Enhancement of long-term potentiation by a potent nitric oxide-guanylyl cyclase activator, 3-(5-hydroxymethyl-2- furyl)-1-benzyl-indazole. Mol. Pharmacol. 63(6), 1322-1328 (2003).
160. Chien WL, Liang KC, Teng CM, Kuo SC, Lee FY, Fu WM. Enhancement of learning behaviour by a potent nitric oxide-guanylate cyclase activator YC-1. Eur. J. Neurosci. 21(6), 1679-1688 (2005).
161. Chien WL, Liang KC, Fu WM. Enhancement of active shuttle avoidance response by the NO-cGMP-PKG activator YC-1. Eur. J. Pharmacol. 590(1-3), 233-240 (2008).
162. Yang X, Wang Y, Luo J, Liu S, Yang Z. Protective effects of YC-1 against glutamate induced PC12 cell apoptosis. Cell Mol. Neurobiol. 31(2), 303-311 (2011).
163. Conti M, Beavo J. Biochemistry and physiology of cyclic nucleotide phosphodiesterases: essential components in cyclic nucleotide signaling. Annu. Rev. Biochem. 76, 481-511 (2007).
164. Bender AT, Beavo JA. Cyclic nucleotide phosphodiesterases: molecular regulation to clinical use. Pharmacol. Rev. 58(3), 488-520 (2006).
165. Reneerkens OA, Rutten K, Steinbusch HW, Blokland A, Prickaerts J. Selective phosphodiesterase inhibitors: a promising target for cognition enhancement. Psychopharmacology (Berl.) 202(1-3), 419-443 (2009).
166. Menniti FS, Faraci WS, Schmidt CJ. Phosphodiesterases in the CNS: targets for drug development. Nat. Rev. Drug Discov. 5(8), 660-670 (2006).
167. Bales KR, Plath N, Svenstrup N, Menniti FS. Phosphodiesterase inhibition to target the synaptic dysfunction in Alzheimer's disease. Top. Med. Chem. 6, 57-59 (2010).
168. Setter SM, Iltz JL, Fincham JE, Campbell RK, Baker DE. Phosphodiesterase 5 inhibitors for erectile dysfunction. Ann. Pharmacother. 39(7-8), 1286-1295 (2005).
169. Devan BD, Sierra-Mercado D, Jr., Jimenez M et al. Phosphodiesterase inhibition by sildenafil citrate attenuates the learning impairment induced by blockade of cholinergic muscarinic receptors in rats. Pharmacol. Biochem. Behav. 79(4), 691-699 (2004).
170. Rutten K, Basile JL, Prickaerts J, Blokland A, Vivian JA. Selective PDE inhibitors rolipram and sildenafil improve object retrieval performance in adult cynomolgus macaques. Psychopharmacology (Berl.) 196(4), 643-648 (2008).
171. Prickaerts J, van Staveren WC, Sik A et al. Effects of two selective phosphodiesterase type 5 inhibitors, sildenafil and vardenafil, on object recognition memory and hippocampal cyclic GMP levels in the rat. Neuroscience 113(2), 351-361 (2002).
172. Prickaerts J, Sik A, van Staveren WC et al. Phosphodiesterase type 5 inhibition improves early memory consolidation of object information. Neurochem. Int. 45(6), 915-928 (2004).
173. Cuadrado-Tejedor M, Hervias I, Ricobaraza A et al. Sildenafil restores cognitive function without affecting beta-amyloid burden in a mouse model of Alzheimer's disease. Br. J. Pharmacol. 164(8), 2029-2041 (2011).
174. Orejana L, Barros-Minones L, Jordan J, Puerta E, Aguirre N. Sildenafil ameliorates cognitive deficits and tau pathology in a senescence-accelerated mouse model. Neurobiol. Aging 33(3), 625 e611-e620 (2012).
175. Palmeri A, Privitera L, Giunta S, Loreto C, Puzzo D. Inhibition of phosphodiesterase-5 rescues age-related impairment of synaptic plasticity and memory. Behav. Brain Res. 240, 11-20 (2013).
176. Fiorito J, Saeed F, Zhang H et al. Synthesis of quinoline derivatives: discovery of a potent and selective phosphodiesterase 5 inhibitor for the treatment of Alzheimer's disease. Eur. J. Med. Chem. 60, 285-294 (2013).
177. Fisher DA, Smith JF, Pillar JS, St Denis SH, Cheng JB. Isolation and characterization of PDE9A, a novel human cGMP-specific phosphodiesterase. J. Biol. Chem. 273(25), 15559-15564 (1998).
178. Andreeva SG, Dikkes P, Epstein PM, Rosenberg PA. Expression of cGMP-specific phosphodiesterase 9A mRNA in the rat brain. J. Neurosci. 21(22), 9068-9076 (2001).
179. van Staveren WC, Glick J, Markerink-van Ittersum M et al. Cloning and localization of the cGMP-specific phosphodiesterase type 9 in the rat brain. J. Neurocytol. 31(8-9), 729-741 (2002).
180. Reyes-Irisarri E, Markerink-Van Ittersum M, Mengod G, de Vente J. Expression of the cGMP-specific phosphodiesterases 2 and 9 in normal and Alzheimer's disease human brains. Eur. J. Neurosci. 25(11), 3332-3338 (2007).
181. Menniti F, Kleiman R, Schmidt C. PDE9A-mediated regulation of cGMP: impact on synaptic plasticity. Schizophrenia Res. 102, 38-39 (2008).
182. Schmidt CJ, Harms J, Tingley FD et al. PDE9A-mediated regulation of cGMP: developing a biomarker for a novel therapy for Alzheimer's disease. Alzheimers Dement. 5(4), P331 (2009).
183. Wunder F, Tersteegen A, Rebmann A, Erb C, Fahrig T, Hendrix M. Characterization of the first potent and selective PDE9 inhibitor using a cGMP reporter cell line. Mol. Pharmacol. 68(6), 1775-1781 (2005).
184. van der Staay FJ, Rutten K, Barfacker L et al. The novel selective PDE9 inhibitor BAY 73-6691 improves learning and memory in rodents. Neuropharmacology 55(5), 908-918 (2008).
185. Verhoest PR, Fonseca KR, Hou X et al. Design and discovery of 6-[(3S,4S)-4-methyl- 1-(pyrimidin-2-ylmethyl)pyrrolidin-3-yl]-1- (tetrahydro-2H-pyr an-4-yl)-1,5-dihydro-4H-pyrazolo[3,4-d]pyrimidin-4-one (PF- 04447943), a selective brain penetrant PDE9A inhibitor for the treatment of cognitive disorders. J. Med. Chem. 55(21), 9045-9054 (2012).
186. Hutson PH, Finger EN, Magliaro BC et al. The selective phosphodiesterase 9 (PDE9) inhibitor PF-04447943 (6-[(3S,4S)-4-methyl- 1-(pyrimidin-2-ylmethyl) pyrrolidin-3-yl]-1- (tetrahydro-2H-py ran-4-yl)-1,5-dihydro-4H-pyrazolo[3,4-d] pyrimidin-4-one) enhances synaptic plasticity and cognitive function in rodents. Neuropharmacology 61(4), 665-676 (2011).
187. Meng F, Hou J, Shao YX et al. Structure-based discovery of highly selective phosphodiesterase-9A inhibitors and implications for inhibitor design. J. Med. Chem. 55(19), 8549-8558 (2012).
188. Vardigan JD, Converso A, Hutson PH, Uslaner JM. The selective phosphodiesterase 9 (PDE9) inhibitor PF-04447943 attenuates a scopolamine-induced deficit in a novel rodent attention task. J. Neurogenet. 25(4), 120-126 (2011).
189. Nicholas T, Evans R, Styren S et al. PF-04447943, a novel PDE9A inhibitor, increases cGMP levels in cerebrospinal fluid: translation from non-clinical species to healthy human volunteers. Alzheimers Dement. 5(4), P330-P331 (2009).
190. Nicholas T, Le V, Qiu R et al. Safety and pharmacokinetics of PF-04447943, a PDE9A inhibitor, in single and multiple dose Phase I studies in healthy volunteers. Alzheimers Dement. 6, S135 (2010).
191. Schwam E, Evans R, Nicholas T et al. PF- 04447943: a Phase II controlled clinical trial of a selective PDE9A inhbitor in Alzheimer's disease. Alzheimers Dement. 7(4), S695 (2011).
192. Wager TT, Chandrasekaran RY, Hou X et al. Defining desirable central nervous system drug space through the alignment of molecular properties, in vitro ADME, and safety attributes. ACS Chem. Neurosci. 1(6), 420-434 (2010).
193. Wager TT, Hou X, Verhoest PR, Villalobos A. Moving beyond rules: the development of a central nervous system multiparameter optimization (CNS MPO) approach to enable alignment of druglike properties. ACS Chem. Neurosci. 1(6), 435-449 (2010).